oc
At ESGCT 2025, @Fesisisimo presented our results from a clinical trial of ALOCELYVIR in children with brain tumors, in a strong collaboration with Dr Álvaro Lassaletta and his team at Hospital Niño Jesús.
@APUpablougarte @AFANION_
@SaludISCIII
We are looking for a postdoctoral researcher with solid expertise in tumor immunology to join our group BIOC (ISCIII), dedicated to immuotherapies on pediatric cancer research.
This opportunity is linked to the AECC postdoctoral fellowships.
Feel free to contact us !!
Our group is presenting our latest results at the CICON25 Congress in Utrecht, a meeting with a special focus on immunotherapy of cancer
@SaludISCIII
In the pilot phase, no clinical responses were observed
in 18 patients unselected TILs.
However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%).
Pembrolizumab
was added, and 8 objective responses were
seen in 34 patients (23.5%)
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies.
Minireview:
frontiersin.org/journals/imm…
78
EsoBiotec SA has launched a clinical trial for ESO-T01, in vivo BCMA CAR-T therapy for multiple myeloma
ESO-T01 reprograms T cells directly using the ENaBL platform, which uses a viral vector said to be “immune shielded” via the removal of MHC1 and the overexpression of CD47
T cell receptor precision editing of regulatory T cells for
celiac disease.
Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs.
e Tregs hold therapeutic potential for restoring gluten
tolerance in their mice model.
science.org/doi/epdf/10.1126…













